The present meta-analysis aimed to systematically evaluates the metastasis, clinical stage, and prognostic value regarding the expression levels of PVT1 in various cancers. Relevant literatures were searched in PubMed?Cochrane Library?Wed of science?Embase databases?Chinese National Knowledge Infrastructure and Wanfang from inception up to 22 August 2017. After data were extracted, a meta-analysis was performed using Review Manager 5.3 and Stata 12.0 software. The meta-analysis showed that high expression of PVT1 could predict more lymph node metastasis (LNM) (Odds ratio, OR=2.83, 95% confidence interval, CI: 1.76-4.54, P<0.0001), distant metastasis (DM) (OR=3.60, 95% CI: 1.08-12.03, P=0.04), advanced clinical stage (OR=4.37, 95% CI: 3.45-5.54, P<0.00001) and poor overall survival (Hazard ratio, HR=2.08, 95% CI: 1.82-2.37, P<0.00001)in cancer. Subgroup analysis in different systems also showed the same results, including respiratory system?digestive system?urinary system and other systems, especially in respiratory system (LNM, OR=4.57, 95% CI: 2.41-8.68, P<0.00001; clinical stage, OR=5.59, 95% CI: 3.59-8.71, P<0.00001; OS, HR=2.43, 95% CI: 1.98-2.99, P<0.00001). These results suggest that PVT1 could serve as a novel biomarker for metastasis, clinical stage and poor prognosis in various tumors.